Pacifico Biolabs Secures €7M for Brewery-Based Protein Production

Pacifico Biolabs has secured €7 million in Series A funding, signaling a significant step forward in its innovative approach to alternative protein production. The capital infusion, led by Stray Dog Capital, with participation from TGFS, Sprout & About Ventures, Simon Capital, FoodLabs, and a strategic regional brewery partner, will fuel the expansion of its mycelium-based protein ingredients. This funding round highlights investor confidence in a model that repurposes existing industrial fermentation capacity, a growing trend as traditional sectors seek diversification.

The company's unique strategy involves utilizing the fermentation tanks found in breweries, a move that dramatically reduces the capital expenditure typically associated with scaling bioprocesses. This is particularly relevant as the European beer market faces shifts in consumer demand, leaving significant infrastructure underutilized. Pacifico Biolabs is effectively transforming this surplus capacity into a valuable asset for the burgeoning alternative protein market, which is projected to reach substantial global figures in the coming decade, driven by sustainability and health consciousness.

This funding will be instrumental in scaling up production at their facility in Saxony, Germany. The company plans to significantly expand its team and accelerate commercial rollouts. Initial market focus will be on the DACH region and Nordic Europe, with ambitious plans for retail launches anticipated by late 2026. This strategic expansion aims to address the critical need for domestically produced protein sources, reducing reliance on imported feedstocks and enhancing supply chain resilience within Europe.

Pacifico Biolabs' technology centers on mycelium fermentation, a process that yields high-quality protein with a favorable nutritional profile and a lower environmental footprint compared to conventional animal agriculture. By integrating with established brewery operations, the company not only benefits from existing infrastructure but also aims to achieve cost efficiencies that bring its products closer to price parity with traditional meat alternatives. This is a crucial factor for widespread consumer adoption in the competitive foodtech sector.

The broader implications of this funding extend beyond Pacifico Biolabs. It underscores a growing trend in the food industry towards circular economy principles and the innovative reuse of industrial assets. As the demand for sustainable protein sources intensifies, companies that can offer scalable, cost-effective, and environmentally sound solutions will be well-positioned for growth. Pacifico Biolabs' model offers a compelling blueprint for how established industrial infrastructure can be adapted to meet future food system needs.

The investment underscores the increasing attractiveness of the alternative protein space for venture capital. With global protein demand set to rise significantly, driven by population growth and evolving dietary preferences, innovative solutions like Pacifico Biolabs' are attracting significant attention. The company's ability to leverage existing, underutilized industrial assets provides a distinct competitive advantage in a capital-intensive sector.